Literature DB >> 12090781

Pharmacology of acute lung injury.

Sadatomo Tasaka1, Naoki Hasegawa, Akitoshi Ishizaka.   

Abstract

The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the anti-inflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090781     DOI: 10.1006/pupt.2001.0325

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  16 in total

Review 1.  Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis.

Authors:  Neill K J Adhikari; Karen E A Burns; Jan O Friedrich; John T Granton; Deborah J Cook; Maureen O Meade
Journal:  BMJ       Date:  2007-03-23

2.  Lung inflammatory responses and hyperinflation induced by an intratracheal exposure to lipopolysaccharide in rats.

Authors:  Anne-Helene Jansson; Christina Eriksson; Xiangdong Wang
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Baicalin ameliorates lipopolysaccharide-induced acute lung injury in mice by suppressing oxidative stress and inflammation via the activation of the Nrf2-mediated HO-1 signaling pathway.

Authors:  Xiangli Meng; Lin Hu; Wenqiang Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-04       Impact factor: 3.000

4.  Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases.

Authors:  Eva Lorenz; Marianne S Muhlebach; Philippe A Tessier; Neil E Alexis; R Duncan Hite; Michael C Seeds; David B Peden; Wayne Meredith
Journal:  Respir Med       Date:  2007-12-27       Impact factor: 3.415

5.  Senegenin Ameliorate Acute Lung Injury Through Reduction of Oxidative Stress and Inhibition of Inflammation in Cecal Ligation and Puncture-Induced Sepsis Rats.

Authors:  Chun-Hong Liu; Wei-Dong Zhang; Jian-Jie Wang; Shan-Dan Feng
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

6.  Iloprost inhibits superoxide formation and gp91phox expression induced by the thromboxane A2 analogue U46619, 8-isoprostane F2alpha, prostaglandin F2alpha, cytokines and endotoxin in the pig pulmonary artery.

Authors:  Saima Muzaffar; Nilima Shukla; Clinton Lobo; Gianni D Angelini; Jamie Y Jeremy
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

7.  Protective effects of alpha-lipoic Acid on oleic Acid-induced acute lung injury in rats.

Authors:  Funda Gülcü Bulmuş; Mehmet Ferit Gürsu; Mehmet Hamdi Muz; Ihsan Yaman; Ozgür Bulmuş; Fatih Sakin
Journal:  Balkan Med J       Date:  2013-09-01       Impact factor: 2.021

Review 8.  Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors.

Authors:  F Kuhr; J Lowry; Y Zhang; V Brovkovych; R A Skidgel
Journal:  Neuropeptides       Date:  2010-01-04       Impact factor: 3.286

9.  Decreased lung hyaluronan in a model of ARDS in the rat: effect of an inhibitor of leukocyte elastase.

Authors:  Chul Min Ahn; Håkan Sandler; Tom Saldeen
Journal:  Ups J Med Sci       Date:  2012-01-27       Impact factor: 2.384

10.  Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration.

Authors:  Reinhold Schmidt; Philipp Markart; Clemens Ruppert; Malgorzata Wygrecka; Tim Kuchenbuch; Dieter Walmrath; Werner Seeger; Andreas Guenther
Journal:  Respir Res       Date:  2007-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.